Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026015 | 0.92 | CCNE1 (0.44) | AURKAKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL5025190 | 0.88 | SMN1; SMN2 (0.42) | KMT2AMEN1MAPTSMN1; SMN2CDK2 | |
| SCHEMBL5029591 | 0.88 | KCNJ5 (0.47) | AURKAKMT2AMEN1MAPTCDK2 | |
| SCHEMBL5027769 | 0.85 | TSHR (0.45) | AURKAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5041435 | 0.85 | AURKA (0.53) | AURKAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5045081 | 0.84 | CCNE1 (0.42) | KMT2AMEN1MAPTTP53SMN1; SMN2 | |
| SCHEMBL12523205 | 0.82 | AURKA (0.51) | AURKAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5046778 | 0.81 | CCNE1 (0.45) | AURKAKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL12455785 | 0.79 | AURKA (0.55) | AURKAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5045023 | 0.78 | AURKA (0.52) | AURKAKMT2AMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| CN-1267431-C | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | AURKA 1/4885KMT2A 909/4885MEN1 1888/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | AURKA 1/4885KMT2A 790/4885MEN1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.